Drug intelligence / Profile preview

bifidobacterium lactis V9 + lactobacillus paracasei LP007 + lactobacillus plantarum PP12

Development stage: Preclinical
Lead developer: Inner Mongolia Aerospace Hospital
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

Bifidobacterium lactis V9 + Lactobacillus paracasei LP007 + Lactobacillus plantarum PP12 is a composite probiotic formulation consisting of three specific bacterial strains. It is currently being evaluated in clinical trials, such as ChiCTR2500107663, for the treatment of irritable bowel syndrome (IBS) in patients with coronary atherosclerosis. The combination is designed to modulate the gut microbiota, potentially influencing the gut-heart-brain axis to alleviate gastrointestinal symptoms and systemic inflammation associated with cardiovascular disease. The development is primarily associated with researchers at the Inner Mongolia Aerospace Hospital and related institutions in China.

Other names: composite probiotic (Bifidobacterium lactis V9, Lactobacillus paracasei LP007, Lactobacillus plantarum PP12)

Targets

AMPK (Adenosine monophosphate–activated protein kinase)

Beyond the preview

Go deeper on bifidobacterium lactis V9 + lactobacillus paracasei LP007 + lactobacillus plantarum PP12.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on bifidobacterium lactis V9 + lactobacillus paracasei LP007 + lactobacillus plantarum PP12.

Explore the full profile